Increased Serum Levels of Fibrinogen Degradation Products Due to Treatment With Recombinant Tissue-Type Plasminogen Activator for Acute Myocardial Infarction Are Related to Bleeding Complications, but Not to Coronary Patency

Journal of the American College of Cardiology - Netherlands
doi 10.1016/0735-1097(89)90096-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Ventricular Arrhythmias During Treatment With Alteplase (Recombinant Tissue Plasminogen Activator) in Suspected Acute Myocardial Infarction.

Heart
Cardiovascular MedicineCardiology
1991English

Acute Coronary Thrombolysis With Recombinant Human Tissue-Type Plasminogen Activator: Initial Patency and Influence of Maintained Infusion on Reocclusion Rate

American Journal of Cardiology
Cardiovascular MedicineCardiology
1987English

Dose Ranging Study of Tissue Plasminogen Activator in Acute Myocardial Infarction.

BMJ
1988English

Acute Myocardial Infarction Due to Coronary Dissection in Early Postpartum

Cor et Vasa
Cardiovascular MedicineCardiology
2016English

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke Can Cause Inferior Myocardial Infarction?

Neurology International
Neurology
2016English

Dose Ranging Study of Tissue Plasminogen Activator in Acute Myocardial Infarction: Authors' Reply

BMJ
1988English

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke

Case Reports in Critical Care
2018English

Soluble HLA-DR Serum Levels Are Associated With Smoking but Not With Acute Coronary Syndrome

Atherosclerosis
Cardiovascular MedicineCardiology
2017English

Intravenous and Intrapulmonary Recombinant Tissue-Type Plasminogen Activator in the Treatment of Acute Massive Pulmonary Embolism

Circulation
Cardiovascular MedicinePhysiologyCardiology
1988English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy